AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 NOV 5 - (NewsRx.com & NewsRx.net) -- MedImmune, Inc., (MEDI) has induced a protective immune response against three of the most serious childhood respiratory viruses in a study incorporating intranasal-vaccine technology similar to that used to develop FluMist (Influenza Virus Vaccine Live, Intranasal).
FluMist is the first nasally delivered influenza vaccine available in the United States. The results of the preclinical study involving parainfluenza-virus type 3 (PIV3), respiratory-syncytial virus (RSV), and human metapneumovirus (hMPV) were published in the October 2003 issue of the Journal of Virology.
"Today, there are no approved vaccines to prevent RSV, hMPV, or PIV3 - three viruses responsible for extensive respiratory illness, and even death, in young children," said Richard Spaete, PhD, senior research director at MedImmune. "Based upon our early results, it appears that we may be able ...
Source: HighBeam Research, MedImmune expands intranasal-vaccine program.